Daniel P. Petrylak - Concepedia

Author

Daniel P. Petrylak

Also Known As

Abraham, Prasanth, Albiges, Laurence, Buckle, Geoffrey C., D P Petrylak, D PETRYLAK, D Petrylak, D. P. PETRYLAK, D. P. Petrylak, D. PETRYLAK, D. Petrylak

830

Publications

45K

Citations

H-Index

153

Concepts

All Affiliations

Yale Cancer Center Yale University Memorial Sloan Kettering Cancer Center Institut Gustave Roussy Cornell University

About

Daniel P. Petrylak is an author at Yale Cancer Center specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	175	18.5K
2	Health Sciences	22	46	1.8K
3	Engineering	3	3	101
4	Natural Sciences	1	1	24
5	Nursing	1	1	12

Daniel P. Petrylak

291

Publications

40.4K

Citations

H-Index

Page 1

	Year	Citations
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain, New England Journal of Medicine	2004	3.7K
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, The Lancet UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2016	3.7K
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, New England Journal of Medicine	2017	3.3K
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Thomas Powles, Joseph P. Eder, Gregg Fine, Nature UrologyOncologyGenitourinary CancerMedicineCancer Treatment	2014	2.4K
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, The Lancet UrologyGenitourinary CancerMedicineFirst-line TreatmentCancer Treatment	2016	2.2K
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma Thomas Powles, Se Hoon Park, Éric Voog, New England Journal of Medicine	2020	1.4K
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak, Journal of Clinical Oncology	2019	1.1K
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde, New England Journal of Medicine	2021	1.1K
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group Glenn J. Bubley, Michael A. Carducci, William L. Dahut, Journal of Clinical Oncology	1999	979
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy George L. Wright, B. Mayer Grob, Cara Haley, Urology AndrologyUrologyProstate-specific Membrane AntigenProstatic DiseaseEndocrinology	1996	624

Page 1